Injectable contraceptive medroxyprogesterone acetate: utilization and experiences among currently married women residing in tea gardens of a block in Darjeeling district, West Bengal, India

Kunal S. Sullar; Louis Tirkey; Kaushik Ishore

doi:10.18203/2320-1770.ijrcog20261614

Authors

Kunal S. Sullar Department of Community Medicine, Maharishi Markandeshwar College of Medical Science and Research, Sadopur, Ambala, Haryana, India
Louis Tirkey Department of Community Medicine, North Bengal Medical College and Hospital, Darjeeling, West Bengal, India
Kaushik Ishore Department of Community Medicine, MJN Medical College and Hospital, Coochbehar, West Bengal, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261614

Keywords:

Contraceptive, Medroxyprogesterone acetate, Side effects, Amenorrhea

Abstract

Background: India has included injectable medroxyprogesterone acetate (MPA) into the Antara Programme to address its high efficacy, though adherence remains a concern. This study assessed the utilization patterns and experiences of currently married women using injectable MPA in tea gardens of Darjeeling district, West Bengal.

Methods: A community-based cross-sectional study was conducted from October 2023 to September 2024 in all tea gardens of Naxalbari block. Complete enumeration included 127 currently married women aged 15–49 years who had received at least one MPA dose in the previous year from sub-centres. Participants were eligible for up to four doses annually. Data were collected through face-to-face interviews using a pre-designed, pre-tested schedule after informed consent, and analyzed using descriptive statistics.

Results: Most participants were aged 21–25 years (34.6%), with a mean age of 26.7±5.8 years, and 50.3% were primiparous. Injectable MPA was the first contraceptive for 55.9% of women, and 95.3% received information from ASHA workers. All women received the first dose, while 84, 75, and 23 received the second, third, and fourth doses, respectively. Side effects were reported by 100, 64, 60, and 19 women after successive doses. Overall, 81.9% discontinued use mainly due to side effects, predominantly amenorrhea. No pregnancies were reported within the three-month effective period after any dose.

Conclusions: Injectable MPA is an effective contraceptive, often used as a first method by young women. ASHA workers facilitate its uptake, but side effects especially amenorrhea is the primary cause for discontinuation.

References

Government of India, Press Information Bureau. Understanding population-related issues, tailoring solutions, and driving progress. New Delhi: Press Information Bureau. 2024. Available at: https://www. pib.gov.in/PressNoteDetails.aspx?NoteId=151925&ModuleId=3®=3&lang=1. Accessed on 10 February 2026.

NITI Aayog. Best Practice Detail. NITI for States (NFS) portal. 2024. Available at: https://nfs.inroad.in/ best-practice-detail?id=103028. Accessed on 10 February 2026.

Patel A, Thakkar J, Patel MS and Khatri SA. A study of use of DMPA (Injectable Contraceptive) in postpartum and postabortal patients. Int J Sci Res. 2019;8(11).

Gupta S, Jakhar R, Manju, Choudhary C. A comparative interventional study to determine the side effects of continuation and discontinuation among women using IUCD and DMPA contraceptive. J Cardiovasc Dis Res. 2024;15(1).

Reference Manual for Injectable Contraceptive (MPA). New Delhi: Family Planning Division Ministry of Health and Family Welfare Government of India. 2016. Available at: https://nhm. gov.in/New_Updates_2018/NHM_Components/RMNCHA/Family_planning/Schemes_&_Guidelines/ Injectable_Contraceptive_MPA.pdf. Accessed on 10 February 2026.

International Institute for Population Sciences (IIPS), Ministry of Health and Family Welfare. National Family Health Survey (NFHS-5), 2019-21: India fact sheet. Mumbai: IIPS. 2021. Available at: https://bogs.org.in/assets/frontend/pdf/India_National_Fact_Sheet.pdf. Accessed on 10 February 2026.

Ministry of Health and Family Welfare; International Institute for Population Sciences (IIPS). National Family Health Survey – 5, 2019-20: District Fact Sheet, Darjeeling, West Bengal. Mumbai: IIPS. 2020. Available at: https://data.opencity.in/dataset/ae 734771-4981-4031-ac38-7c056aa2c0c0/resource/ 14194097-30ac-4a83-8b4a41bd584337a2/download /0532da12-753e-45c3-afc6-fbdaa6fb071a.pdf. Accessed on 10 February 2026.

Shilpa MN, Shwetha M. Profile and compliance of recipients of injection depot medroxy progesterone acetate as a contraceptive method in the government tertiary care hospital in Mandya, South Karnataka, India. Int J Reprod Contracept Obstet Gynecol. 2020;9(2):507-12.

Mane NS, Rokade JV. Study the acceptance, compliance and efficacy of injection depot medroxy progesterone acetate as contraception: A prospective observational study. Int J Reprod Contracept Obstet Gynecol. 2021;10(1):303-8.

Agrawal S, Sood S, Chopra K, Singh A, Gupta A, Singh S, Puri M. Insights from client experience with injection medroxyprogesterone acetate (MPA) in India: lessons from the field. J Obstet Gynecol India. 2022;72:262-6.

Rajaraman R, Vaithilingan S, Selvavinayagam TS, Vaithilingan Sr S, Selvavinayagam TS. Acceptance, Adherence, and Side Effects of Depot Medroxyprogesterone Acetate: A Prospective Observational Study. Cureus. 2024;16(4).

Nautiyal R, Bijalwan R, Maithili B, Sinha LN. Feasibility of injectable Depot medroxyprogesterone acetate in a semi urban camp setting. Int J Reprod Contracept Obstet Gynecol. 2016;5(4):1056-60.

Gupta V, Chawla S, Gour N, Goel PK. Determinants of injectable depot medroxyprogesterone acetate contraception among women of reproductive age: A study from Southern Haryana, India. Indian J Comm Family Med. 2020;6(2):144-9.

Fonseca M, Deshmukh PY, Kharat D. DMPA: acceptance and compliance in a tertiary care hospital in Mumbai, India. Int J Reprod Contracept Obstet Gynecol. 2017;6(9):3879-81.

Mishra S, Gupta R. Acceptability and compliance of DMPA among rural women in Sitapur UP. Headache. 2019;5(1):3.

Khan ME, Dixit A, Ahmad J, Pillai G. Introduction of DMPA in public health facilities of Uttar Pradesh and Rajasthan: An evaluation. 2015. Available at: https://knowledgecommons.popcouncil.org/cgi/viewcontent.cgi?article=1905&context=departments_sbsr-rh. Accessed on 10 February 2026.

Samal S, Das L. Study of depot medroxyprogesterone acetate as an extended postpartum contraceptive at SCB medical college and hospital, Cuttack. Int J Reprod Contracept Obstet Gynecol. 2021;10(4):1484-91.

Nigam N, Mishra J, Rathod I. Assess the acceptance and compliance of injectable contraceptive depot medroxyprogestrone acetate. Int J Reprod Contracept Obstet Gynecol. 2023;12:2508-13.